Iambic Therapeutics, an Nvidia-backed AI drug-discovery company, priced a $150 million initial public offering and is set to begin trading this week. The cancer-focused biotech sold 9.38 million shares at $16 each, positioning the company to advance an early-stage pipeline built around machine-learning driven discovery. For investors and partners, the move underscores how capital markets are funding new platform-style oncology entrants that aim to compress early discovery timelines. Market attention will likely center on the company’s target selection, molecule progressions into preclinical packages, and the evidence base tying its models to functional biology. The IPO also adds to a growing roster of young, AI-first biotechs using public markets to finance discovery-risk—while offering fewer near-term clinical milestones than traditional funding rounds. Near-term catalysts will be any disclosed lead assets, preclinical data readouts, and the pace at which candidates progress toward IND-enabling studies.